

Supplementary material for Tuxen M. K. et al. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide \pm trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol 2014; 53:1440–1445.

Supplementary Table I. Grade 3-4 toxicities (47 patients).

Adverse events grade 3-4	Number (%)
Palmar-plantar erythrodysesthesia (PPE)	16 (34)
Pain (myalgia + arthralgia)	15 (31)
Neurotoxicity	10 (21)
Fatigue	10 (21)
Febrile neutropenia	9 (19)
Mucositis	4 (8)
Nausea, vomiting	2 (4)
Hypersensitivity	1 (2)
Nail disorders	1 (2)

Supplementary Table II. Trials with neoadjuvant chemotherapy in primary breast cancer.

Author	Number of patients	Regimen	PR+ CR (%)	CR (%)	pCR (%)
Buzdar et al. [7]	87	P d1 q3w x 4	80	27	8
	87	FAC d1 q3w x 4	79	24	17
Miller et al. [8]	19	D d1 q2w x 3 \rightarrow A d1 q2w x 3	89	32	16
	21	AD d1 q3w x 4	81	10	10
Bujanda et al. [9]	49	EC d1 + T d1,8,15,22 q4w x 3-4	84	33	15
Evans et al. [10]	180	AC d1 q3w x 6	61	17	24
	183	AD d1 q3w x 6	66	20	21
Kelly et al. [11]	37	AC d1 q3w x 4 \rightarrow TP d1 q1w x 12	86	56	19
Rocca et al. [12]	58	E d1,2 + CIS d1 q3w + FU daily x 6	58		41
Tiezzi et al. [13]	60	ED d1 q3w	77	15	5
Gogas et al. [14]	35	P+ PLD d1 q3w x 6	71	17	9
Rossi et al. [15]	35	P d1,8 + PLD d1 q2w x 4	74	8	9
Artioli et al. [16]	50	G d1,8 + D d8 + PLD d8 q3w x 4-6	74	26	16
Dellapasqua et al. [17]	29	PLD d1 q2w x 8 + C daily	62	0	3
Taguchi et al. [18]	47	P d1,8,15 q3w x 4 \rightarrow FEC d1 q3w x 4	85	38	28
Therasse et al. [19]	224	C d1 - 14 + EF d1,8 q4w x 6	89	31	14
	224	EC (high dose) d1 q3w x 6	91	27	10
Gianni et al. [20,21]	117 (HER2 positive)	T+AP d1 q3w x 3 \rightarrow T+P d1 q3w x 4 \rightarrow T+CMF d1 q4w x 3	87	60	38
	118 (HER2 positive)	AP d1 q3w x 3 \rightarrow P d1 q3w x 4 \rightarrow CMF d1 q4w x 3	74	51	19
	99 (HER2 negative)	AP d1 q3w x 3 \rightarrow P d1 q3w x 4 \rightarrow CMF d1 q4w x 3	71	25	16

A, doxorubicin; C, cyclophosphamide; CIS, cisplatin; CR, complete response; D, docetaxel; E, epirubicin; F, 5-fluorouracil; G, gemcitabine; M, methotrexate; P, paclitaxel; pCR, pathological complete response; PLD, pegylated liposomal doxorubicin; PR, partial response; T, trastuzumab; V, vincristin.



Supplementary Figure 1. Patient with palmar-plantar erythrodysesthesia.